The substantiation of scientific and methodical approaches to identification and evaluation of risks in parenteral medical forms combined production

A. M. Goy, O. V. Posylkina, Y. N. Derenska, M. I. Borshchevska

Abstract


The article analyzes the scientific approaches to the assessment and minimization of the risks of cross contamination in the conditions of combined production, proposed an algorithm for the preliminary assessment of the risks of combined production of parenteral medical forms, developed an algorithm for a formalized assessment of the risks of cross contamination, the expert method substantiated the critical stages, the most significant factors and sources of risks of cross contamination of combined production of parenteral medical forms.
Aim. To identify the factors and sources of risk of co-production of parenteral medical forms, to develop algorithms for assessing the risks of joint production of parenteral medical forms and formalized assessment of the risks of cross contamination.
Materials and methods. Great attention was paid to preliminary assessment of the risks in combined production of parenteral medical forms; algorithm for a formalized assessment of the risks of cross contamination was taken into account; the expert method substantiated the critical stages.
Results. Eleven stages of assessing the risks of combined production of parenteral drugs, four critical stages, three most significant factors and four most significant sources of risk of cross contamination were identified.
Conclusions. The identified critical stages, factors, and sources of risk of cross contamination make it possible to identify benchmarks for assessing the risk of contamination of the combined production of parenteral medical forms.


Keywords


cross contamination; identification of risks; formalized risk assessment algorithm

References


Hoy, А. M., Voskoboinikova, H. L., Hapon, N. V. (2016). Fаrmаkоm, 2, 63–70.

Nastanova SТ–N МОZU 42–4.2:2011. Likarski zasoby. Upravlinnia ryzykamy dlia yakosti (ІСН Q9). (2011).

Кyiv: МОZ Ukrainy, 35.

Pomeshcheniia i zony farmatcevticheskogo predpriiatiia – proektirovanie, montazh, ekspluatatciia. (2010).

Farmatsevticheskaia otrasl, 1(18). Available at: http://archive.promoboz.com/n1_18/12–13.pdf

Spitskii, О. R. Provedenie analiza riskov pri proektirovanii i validatcii farmatcevticheskogo proizvodstva.

Available at: http://www.medbusiness.ru/440.php

Kostiuk, H. V. (2008). Vprovadzhennia pryntsypiv proektnoho menedzhmentu na farmatsevtychnykh pidpryiemstvakh

Ukrainy. Sohodennia ta maibutnie farmatsii. Kharkiv: NFаU, 535–536.

Lebedinets, V. A., Bursakov, A. V. (2008). Provisor, 17, 26–28.

Bart, J. (2010). 10 golden rules of project risk management. PROGECT SMART. Available at: https://www.

projectsmart.co.uk/10–golden–rules–of–project–risk–management.php

Lysenko, I. I. (2012). Farmatcevticheskaia otrasl, 1 (30), 92–93.

EMEA: White Paper, In Response to the EMEA’s Concept Paper. Dealing with the Need for Updated GMP

Guidance Concerning Dedicated Manufacturing Facilities in the Manufacture of Certain Medicinal Products.

Available at: http://ec.europa.eu/health/human–use/quality/developements/index_en.htm

Wilkins, S. (2008). Risk–MaPP: Manging the risk of cross contamination. Doc. Ref. EMEA/INS/GMP, 5,

Doc. № 14529.


GOST Style Citations


1. Гой, А. М. Концептуальні підходи до визначення методології проектного менеджменту сучасного
фармацевтичного виробництва парентеральних лікарських форм на основі рекомбінантних біл-
ків / А. М. Гой, Г. Л. Воскобойнікова, Н. В. Гапон // Фармаком. – 2016. – № 2. – С. 63–70.

2. Лікарські засоби. Управління ризиками для якості (ІСН Q9) : настанова СТ–Н МОЗУ 42–4.2:2011.
– К. : МОЗ України, 2011. – 35 с.

3. Помещения и зоны фармацевтического предприятия – проектирование, монтаж, эксплуатация
[Электронный ресурс] // Фармац. отрасль. – 2010. – № 1 (18). – Режим доступа : http://archive.promoboz.
com/n1_18/12–13.pdf

4. Спицкий, О. Р. Проведение анализа рисков при проектировании и валидации фармацевтического
производства [Электронный ресурс] / О. Р. Спицкий. – Режим доступа : http://www.medbusiness.
ru/440.php

5. Костюк, Г. В. Впровадження принципів проектного менеджменту на фармацевтичних підприємствах України / Г. В. Костюк, В. О. Лебединець // Сьогодення та майбутнє фармації : тез. доп. Все-
укр. конгр. 16–19 квіт. 2008 р. – Х. : НФаУ, 2008. – С. 535–536.

6. Лебединец, В. А. Анализ актуальности интегрированных систем менеджмента в фармации / В. А. Лебединец, А. В. Бурсаков // Провизор. – 2008. – № 17. – С. 26–28.

7. Bart, J. 10 golden rules of project risk management / J. Bart. – PROGECT SMART, 2010. – Available at :
https://www.projectsmart.co.uk/10–golden–rules–of–project–risk–management. php

8. Лысенко, И. И. Валидация процесса заполнения (Media Fill Test – MFT) лекарственных средств
парентерального введения / И. И. Лысенко // Фармац. отрасль. – 2012. – № 1 (30). – С. 92–93.

9. EMEA : White Paper, In Response to the EMEA’s Concept Paper. Dealing with the Need for Updated
GMP Guidance Concerning Dedicated Manufacturing Facilities in the Manufacture of Certain Medicinal
Products. – Available at : http://ec.europa.eu/health/human–use/quality/developements/index_en.htm

10. Risk–MaPP : Manging the risk of cross contamination / S. Wilkins // Doc. Ref. EMEA/INS/GMP. – 2008.
– Vol. 5. – Doc. № 14529.





DOI: https://doi.org/10.24959/uekj.17.29

Abbreviated key title: Upr. ekon. zabezp. âkostì farm.

ISSN 2519-8807 (Online), ISSN 2311-1127 (Print)